These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18379033)

  • 1. [Cancer treatment-induced bone loss. Treatment for breast cancer].
    Yamada K; Kohno N
    Clin Calcium; 2008 Apr; 18(4):507-17. PubMed ID: 18379033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
    Takahashi S
    Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?
    Lønning PE
    J Clin Oncol; 2008 Oct; 26(30):4859-61. PubMed ID: 18725646
    [No Abstract]   [Full Text] [Related]  

  • 4. [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
    Takahashi S
    Clin Calcium; 2011 Aug; 21(8):1239-47. PubMed ID: 21814031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
    Brufsky AM
    Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy with bone-targeted agents.
    Wilson C; Coleman RE
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
    Tang SC
    Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
    J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab an option for patients with bone metastasis from breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
    [No Abstract]   [Full Text] [Related]  

  • 12. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
    Goessl C; Katz L; Dougall WC; Kostenuik PJ; Zoog HB; Braun A; Dansey R; Wagman RB
    Ann N Y Acad Sci; 2012 Aug; 1263():29-40. PubMed ID: 22831177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term implications of bone loss in breast cancer.
    Aapro MS
    Breast; 2004 Dec; 13 Suppl 1():S29-37. PubMed ID: 15585380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of bone loss induced by aromatase inhibitors.
    Gnant M
    Cancer Invest; 2006; 24(3):328-30. PubMed ID: 16809162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab and the current status of bone-modifying drugs in breast cancer.
    Lee BL; Higgins MJ; Goss PE
    Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiresorptive therapies in oncology and their effects on cancer progression.
    Bundred N
    Cancer Treat Rev; 2012 Oct; 38(6):776-86. PubMed ID: 22370427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments for treatment and prevention of bone metastases.
    Body JJ
    Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid prevents cancer treatment-induced bone loss.
    Oncology (Williston Park); 2005 Mar; 19(3):390. PubMed ID: 15828553
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging drugs for the management of cancer treatment induced bone loss.
    Bertoldo F; Pancheri S; Zenari S; Boldini S
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):323-42. PubMed ID: 20377485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.